Isabelle Rooney Selected Research

cobimetinib

1/2020	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
1/2019	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.
11/2018	Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.
1/2018	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
1/2018	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
9/2017	Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
9/2016	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
11/2013	Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isabelle Rooney Research Topics

Disease

7	Melanoma (Melanoma, Malignant) 01/2020 - 09/2016
5	Neoplasms (Cancer) 01/2019 - 11/2013
2	Disease Progression 01/2019 - 09/2016
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Obesity 01/2018
1	Overweight 01/2018
1	Fever (Fevers) 09/2016
1	Dehydration (Water Stress) 09/2016
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2014
1	Renal Insufficiency (Renal Failure) 04/2013
1	Cystic Fibrosis (Mucoviscidosis) 01/2005

Drug/Important Bio-Agent (IBA)

8	cobimetinibIBA 01/2020 - 11/2013
7	VemurafenibIBA 01/2020 - 09/2016
2	RNA (Ribonucleic Acid)IBA 01/2019 - 11/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 11/2018
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	Mitogen-Activated Protein KinasesIBA 11/2018
1	Dacarbazine (DIC)FDA LinkGeneric 01/2018
1	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2018
1	trametinibIBA 01/2018
1	dabrafenibIBA 01/2018
1	pembrolizumabIBA 01/2018
1	Bevacizumab (Avastin)FDA Link 01/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018
1	IpilimumabIBA 01/2018
1	Letrozole (Femara)FDA LinkGeneric 01/2018
1	NivolumabIBA 01/2018
1	atezolizumabIBA 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2018
1	A 7 (A-7)IBA 09/2016
1	Proteins (Proteins, Gene)FDA Link 12/2014
1	Messenger RNA (mRNA)IBA 12/2014
1	Biomarkers (Surrogate Marker)IBA 12/2014
1	Matrix Metalloproteinases (MMPs)IBA 12/2014
1	Monoclonal AntibodiesIBA 12/2014
1	Small Interfering RNA (siRNA)IBA 12/2014
1	NitrogenIBA 04/2013
1	CreatinineIBA 04/2013
1	Urea (Carbamide)FDA LinkGeneric 04/2013
1	NucleotidesIBA 01/2005
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2005

Therapy/Procedure

3	Therapeutics 01/2019 - 12/2014
1	Drug Therapy (Chemotherapy) 01/2018
1	Immunotherapy 01/2018